PRAME and hematologic disorder: PRAME is also overexpressed in some cancers, such as breast cancer, cervical cancer, lung cancer, ovarian cancer, melanoma, sarcoma and hematological malignancies, and its function in these cancers depends on the tumor type and downstream targets that mediate cell differentiation, proliferation, apoptosis, growth arrest and chemotherapy sensitivity (16–25).